The peptide landscape just shifted. Here's the honest breakdown.
If you follow health news, you've probably seen the headlines: peptides are "coming back." There's real news behind the noise — but there's also a lot of hype, and a few things worth understanding before you act on any of it.
Here's the straight version.
What changed
In late 2023, the FDA moved a group of widely used peptides — including names you may recognize like BPC-157, TB-500, and CJC-1295 — onto a restricted list that effectively kept compounding pharmacies from preparing them.
As of April 23, 2026, many of those peptides came off that restricted list. An FDA advisory committee is scheduled to meet in late July 2026 to review them further.
So yes — access is opening back up.
What it does not mean
Here's the part the hype skips: coming off the restricted list is not the same as FDA approval. It means licensed physicians and compounding pharmacies can work with these peptides again — not that they're safe to grab off the internet from whoever's selling.
That distinction is everything.
Why this is exactly where we come in
These peptides are powerful tools when used correctly — and a gamble when they're not. Dosing, timing, how they're combined, and how they fit your body and your bloodwork all require real medical expertise. Social media is full of peptide advice from people with none.
That's the whole reason Revive7 exists. We pair comprehensive bloodwork with physician-guided protocols, so what you take is based on your actual data — not a trend, not an influencer, not a guess.
If you've been curious about peptide therapy, this is a good moment to have a real conversation. Not a sales pitch — a consultation focused on your goals, your labs, and what's actually appropriate for you.
Repair. Rebuild. Optimize.
— The Revive7 Team
This newsletter is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Peptide therapy should be pursued only under licensed medical supervision.